Douglas E. Williams

Douglas E. Williams, Ph.D. is a seasoned industry leader with over 30 years of experience in the U.S. biotechnology industry. He currently is President and Chief Executive Officer and member of the Board of Codiak BioSciences. He was previously Executive Vice President, Research and Development, at Biogen. Prior to that he was Chief Executive Officer and member of the Board of ZymoGenetics. ZymoGenetics was purchased for $985 million by Bristol-Myers Squibb during Dr. Williams’ tenure. Other leadership positions have included Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams also served in a series of leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer. He has contributed to the development of several novel drugs, including Enbrel® (etanercept), Tecfidera® (dimethyl fumarate), and Spinraza® (nusinersen). He is currently a member of the Board of Directors of Ovid Therapeutics, and Chairman of the Board of AC Immune.